HIV DNA vaccine: Stepwise improvements make a difference

Vaccines

Volumn 2, Issue 2, 2014, Pages 354-379

  Felber, Barbara K ^a   Valentin, Antonio ^a   Rosati, Margherita ^a   Bergamaschi, Cristina ^a   Pavlakis, George N ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cytokine; DNA delivery; DNA expression; Electroporation; Immunogenicity; Macaque; Plasmid; Vaccination

Indexed keywords

BETA CATENIN; CD40 LIGAND; DNA VACCINE; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; LIVE VACCINE; RANTES; REV PROTEIN; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; UBIQUITIN; VIRUS ENVELOPE PROTEIN;

ANTIGEN EXPRESSION; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; ELECTROPORATION; GENE EXPRESSION; GENE GUN; GENE TARGETING; GENE TRANSFER; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; JET INJECTOR; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SEQUENCE HOMOLOGY; TRANSDERMAL PATCH;

EID: 85019487978     PISSN: None     EISSN: 2076393X     Source Type: Journal    
DOI: 10.3390/vaccines2020354     Document Type: Review

References (212)

1. Berman, P.W. Development of bivalent rgp120 vaccines to prevent HIV type 1 infection. AIDS Res. Hum. Retroviruses 1998, 14, S277-S289.
2. Francis, D.P.; Gregory, T.; McElrath, M.J.; Belshe, R.B.; Gorse, G.J.; Migasena, S.; Kitayaporn, D.; Pitisuttitham, P.; Matthews, T.; Schwartz, D.H.; et al. Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3. AIDS Res. Hum. Retroviruses 1998, 14, S325-S331.
3. Pitisuttithum, P.; Gilbert, P.; Gurwith, M.; Heyward, W.; Martin, M.; van Griensven, F.; Hu, D.; Tappero, J.W.; Choopanya, K. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 2006, 194, 1661-1671.
4. Flynn, N.M.; Forthal, D.N.; Harro, C.D.; Judson, F.N.; Mayer, K.H.; Para, M.F. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 2005, 191, 654-665.
5. McElrath, M.J.; de Rosa, S.C.; Moodie, Z.; Dubey, S.; Kierstead, L.; Janes, H.; Defawe, O.D.; Carter, D.K.; Hural, J.; Akondy, R.; et al. HIV-1 vaccine-induced immunity in the test-of-concept step study: A case-cohort analysis. Lancet 2008, 372, 1894-1905.
6. Rolland, M.; Tovanabutra, S.; deCamp, A.C.; Frahm, N.; Gilbert, P.B.; Sanders-Buell, E.; Heath, L.; Magaret, C.A.; Bose, M.; Bradfield, A.; et al. Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat. Med. 2011, 17, 366-371.
7. Buchbinder, S.P.; Mehrotra, D.V.; Duerr, A.; Fitzgerald, D.W.; Mogg, R.; Li, D.; Gilbert, P.B.; Lama, J.R.; Marmor, M.; del Rio, C.; et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008, 372, 1881-1893.
8. Hammer, S.M.; Sobieszczyk, M.E.; Janes, H.; Karuna, S.T.; Mulligan, M.J.; Grove, D.; Koblin, B.A.; Buchbinder, S.P.; Keefer, M.C.; Tomaras, G.D.; et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N. Engl. J. Med. 2013, 369, 2083-2092.
9. Rerks-Ngarm, S.; Pitisuttithum, P.; Nitayaphan, S.; Kaewkungwal, J.; Chiu, J.; Paris, R.; Premsri, N.; Namwat, C.; de Souza, M.; Adams, E.; et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 2009, 361, 2209-2220.
10. Rolland, M.; Edlefsen, P.T.; Larsen, B.B.; Tovanabutra, S.; Sanders-Buell, E.; Hertz, T.; deCamp, A.C.; Carrico, C.; Menis, S.; Magaret, C.A.; et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 2012, 490, 417-420.
11. Haynes, B.F.; Gilbert, P.B.; McElrath, M.J.; Zolla-Pazner, S.; Tomaras, G.D.; Alam, S.M.; Evans, D.T.; Montefiori, D.C.; Karnasuta, C.; Sutthent, R.; et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 2012, 366, 1275-1286.
12. Gottardo, R.; Bailer, R.T.; Korber, B.T.; Gnanakaran, S.; Phillips, J.; Shen, X.; Tomaras, G.D.; Turk, E.; Imholte, G.; Eckler, L.; et al. Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS One 2013, 8, e75665.
13. Zolla-Pazner, S.; deCamp, A.C.; Cardozo, T.; Karasavvas, N.; Gottardo, R.; Williams, C.; Morris, D.E.; Tomaras, G.; Rao, M.; Billings, E.; et al. Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. PLoS One 2013, 8, e53629.
14. Karasavvas, N.; Billings, E.; Rao, M.; Williams, C.; Zolla-Pazner, S.; Bailer, R.T.; Koup, R.A.; Madnote, S.; Arworn, D.; Shen, X.; et al. The Thai phase III HIV type 1 vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res. Hum. Retroviruses 2012, 28, 1444-1457.
15. Ferraro, B.; Morrow, M.P.; Hutnick, N.A.; Shin, T.H.; Lucke, C.E.; Weiner, D.B. Clinical applications of DNA vaccines: Current progress. Clin. Infect. Dis. 2011, 53, 296-302.
16. Salonius, K.; Simard, N.; Harland, R.; Ulmer, J.B. The road to licensure of a DNA vaccine. Curr. Opin. Investig. Drugs 2007, 8, 635-641.
17. Ulmer, J.B.; Wahren, B.; Liu, M.A. DNA vaccines for HIV/AIDS. Curr. Opin. HIV AIDS 2006, 1, 309-313.
18. Bunning, M.L.; Bowen, R.A.; Cropp, B.; Sullivan, K.; Davis, B.; Komar, N.; Godsey, M.; Baker, D.; Hettler, D.; Holmes, D.; et al. Experimental infection of horses with West Nile virus and their potential to infect mosquitoes and serve as amplifying hosts. Ann. NY Acad. Sci. 2001, 951, 338-339.
19. Davis, B.S.; Chang, G.J.; Cropp, B.; Roehrig, J.T.; Martin, D.A.; Mitchell, C.J.; Bowen, R.; Bunning, M.L. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J. Virol. 2001, 75, 4040-4047.
20. Bergman, P.J.; McKnight, J.; Novosad, A.; Charney, S.; Farrelly, J.; Craft, D.; Wulderk, M.; Jeffers, Y.; Sadelain, M.; Hohenhaus, A.E.; et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: A phase I trial. Clin. Cancer Res. 2003, 9, 1284-1290.
21. Traxler, G.S.; Anderson, E.; LaPatra, S.E.; Richard, J.; Shewmaker, B.; Kurath, G. Naked DNA vaccination of Atlantic salmon Salmo salar against IHNV. Dis. Aquat. Organ. 1999, 38, 183-190.
22. Corbeil, S.; Lapatra, S.E.; Anderson, E.D.; Jones, J.; Vincent, B.; Hsu, Y.L.; Kurath, G. Evaluation of the protective immunogenicity of the N, P, M, NV and G proteins of infectious hematopoietic necrosis virus in rainbow trout oncorhynchus mykiss using DNA vaccines. Dis. Aquat. Organ. 1999, 39, 29-36.
23. Garver, K.A.; LaPatra, S.E.; Kurath, G. Efficacy of an infectious hematopoietic necrosis (IHN) virus DNA vaccine in Chinook Oncorhynchus tshawytscha and sockeye O. nerka salmon. Dis. Aquat. Organ. 2005, 64, 13-22.
24. Patel, V.; Jalah, R.; Kulkarni, V.; Valentin, A.; Rosati, M.; Alicea, C.; von Gegerfelt, A.; Huang, W.; Guan, Y.; Keele, B.; et al. DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous SIV challenge. Proc. Natl. Acad. Sci. USA 2013, 110, 2975-2980.
25. Rosati, M.; Bergamaschi, C.; Valentin, A.; Kulkarni, V.; Jalah, R.; Patel, V.; von Gegerfelt, A.S.; Montefiori, D.C.; Venzon, D.; Khan, A.S.; et al. DNA vaccination in rhesus macaques induces potent immune responses and decreases acute and chronic viremia after SIVmac251 challenge. Proc. Natl. Acad. Sci. USA 2009, 106, 15831-15836.
26. Rosati, M.; von Gegerfelt, A.; Roth, P.; Alicea, C.; Valentin, A.; Robert-Guroff, M.; Venzon, D.; Montefiori, D.C.; Markham, P.; Felber, B.K.; et al. DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge. J. Virol. 2005, 79, 8480-8492.
27. Cristillo, A.D.; Galmin, L.; Restrepo, S.; Hudacik, L.; Suschak, J.; Lewis, B.; Draghia-Akli, R.; Aziz, N.; Weiss, D.; Markham, P.; et al. HIV-1 Env vaccine comprised of electroporated DNA and protein co-administered with Talabostat. Biochem. Biophys. Res. Commun. 2008, 370, 22-26.
28. Patel, V.; Valentin, A.; Kulkarni, V.; Rosati, M.; Bergamaschi, C.; Jalah, R.; Alicea, C.; Minang, J.T.; Trivett, M.T.; Ohlen, C.; et al. Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization. Vaccine 2010, 28, 4827-4836.
29. Jalah, R.; Kulkarni, V.; Patel, V.; Rosati, M.; Alicea, C.; Bear, J.; Yu, L.; Guan, Y.; Shen, X.; Tomaras, G.D.; et al. DNA and protein co-immunization improves the magnitude and longevity of humoral immune responses in rhesus macaques. PLoS One 2014, 9, e91550.
30. Felber, B.K.; Zolotukhin, A.S.; Pavlakis, G.N. Posttranscriptional control of HIV-1 and other retroviruses and its practical applications. Adv. Pharmacol. 2007, 55, 161-197.
31. Cochrane, A.W.; McNally, M.T.; Mouland, A.J. The retrovirus RNA trafficking granule: From birth to maturity. Retrovirology 2006, 3, e18.
32. Chen, C.Y.; Liu, X.; Boris-Lawrie, K.; Sharma, A.; Jeang, K.T. Cellular RNA helicases and HIV-1: Insights from genome-wide, proteomic, and molecular studies. Virus Res. 2013, 171, 357-365.
33. Yedavalli, V.S.; Jeang, K.T. Rev-ing up post-transcriptional HIV-1 RNA expression. RNA Biol. 2011, 8, 195-199.
34. Felber, B.K.; Hadzopoulou-Cladaras, M.; Cladaras, C.; Copeland, T.; Pavlakis, G.N. rev Protein of human immunodeficiency virus type 1 affects the stability and transport of the viral mRNA. Proc. Natl. Acad. Sci. USA 1989, 86, 1495-1499.
35. Sodroski, J.; Goh, W.C.; Rosen, C.; Dayton, A.; Terwilliger, E.; Haseltine, W. A second post-transcriptional trans-activator gene required for HTLV-III replication. Nature 1986, 321, 412-417.
36. Feinberg, M.B.; Jarrett, R.F.; Aldovini, A.; Gallo, R.C.; Wong-Staal, F. HTLV-III expression and production involve complex regulation at the levels of splicing and translation of viral RNA. Cell 1986, 46, 807-817.
37. Hadzopoulou-Cladaras, M.; Felber, B.K.; Cladaras, C.; Athanassopoulos, A.; Tse, A.; Pavlakis, G.N. The rev (trs/art) protein of human immunodeficiency virus type 1 affects viral mRNA and protein expression via a cis-acting sequence in the env region. J. Virol. 1989, 63, 1265-1274.
38. Malim, M.H.; Hauber, J.; Le, S.Y.; Maizel, J.V.; Cullen, B.R. The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature 1989, 338, 254-257.
39. Schneider, R.; Campbell, M.; Nasioulas, G.; Felber, B.K.; Pavlakis, G.N. Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle formation. J. Virol. 1997, 71, 4892-4903.
40. Schwartz, S.; Campbell, M.; Nasioulas, G.; Harrison, J.; Felber, B.K.; Pavlakis, G.N. Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression. J. Virol. 1992, 66, 7176-7182.
41. Schwartz, S.; Felber, B.K.; Pavlakis, G.N. Distinct RNA sequences in the gag region of human immunodeficiency virus type 1 decrease RNA stability and inhibit expression in the absence of Rev protein. J. Virol. 1992, 66, 150-159.
42. Nasioulas, G.; Zolotukhin, A.S.; Tabernero, C.; Solomin, L.; Cunningham, C.P.; Pavlakis, G.N.; Felber, B.K. Elements distinct from human immunodeficiency virus type 1 splice sites are responsible for the Rev dependence of env mRNA. J. Virol. 1994, 68, 2986-2993.
43. Cochrane, A.W.; Jones, K.S.; Beidas, S.; Dillon, P.J.; Skalka, A.M.; Rosen, C.A. Identification and characterization of intragenic sequences which repress human immunodeficiency virus structural gene expression. J. Virol. 1991, 65, 5305-5313.
44. Rosen, C.A.; Terwilliger, E.; Dayton, A.; Sodroski, J.G.; Haseltine, W.A. Intragenic cis-acting art gene-responsive sequences of the human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 1988, 85, 2071-2075.
45. Wallace, A.; West, K.; Rothman, A.L.; Ennis, F.A.; Lu, S.; Wang, S. Post-translational intracellular trafficking determines the type of immune response elicited by DNA vaccines expressing Gag antigen of Human Immunodeficiency Virus Type 1 (HIV-1). Hum. Vaccin Immunother. 2013, 9, 2095-2102.
46. Wang, S.; Farfan-Arribas, D.J.; Shen, S.; Chou, T.H.; Hirsch, A.; He, F.; Lu, S. Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine. Vaccine 2006, 24, 4531-4540.
47. Kulkarni, V.; Rosati, M.; Valentin, A.; Ganneru, B.; Singh, A.K.; Yan, J.; Rolland, M.; Alicea, C.; Beach, R.K.; Zhang, G.M.; et al. HIV-1 p24gag derived conserved element DNA vaccine increases the breadth of immune response in mice. PLoS One 2013, 8, e60245
48. Kumar, S.; Yan, J.; Muthumani, K.; Ramanathan, M.P.; Yoon, H.; Pavlakis, G.N.; Felber, B.K.; Sidhu, M.; Boyer, J.D.; Weiner, D.B. Immunogenicity testing of a novel engineered HIV-1 envelope gp140 DNA vaccine construct. DNA Cell Biol. 2006, 25, 383-392.
49. Kulkarni, V.; Jalah, R.; Ganneru, B.; Bergamaschi, C.; Alicea, C.; von Gegerfelt, A.; Patel, V.; Zhang, G.M.; Chowdhury, B.; Broderick, K.E.; et al. Comparison of immune responses generated by optimized DNA vaccination against SIV antigens in mice and macaques. Vaccine 2011, 29, 6742-6754.
50. Valentin, A.; Chikhlikar, P.; Patel, V.; Rosati, M.; Maciel, M.; Chang, K.H.; Silvera, P.; Felber, B.K.; Pavlakis, G.N.; August, J.T.; et al. Comparison of DNA vaccines producing HIV-1 Gag and LAMP/Gag chimera in rhesus macaques reveals antigen-specific T-cell responses with distinct phenotypes. Vaccine 2009, 27, 4840-4849.
51. Chikhlikar, P.; de Arruda, L.B.; Maciel, M.; Silvera, P.; Lewis, M.G.; August, J.T.; Marques, E.T. DNA encoding an HIV-1 Gag/human lysosome-associated membrane protein-1 chimera elicits a broad cellular and humoral immune response in rhesus macaques. PLoS One 2006, 1, e135.
52. Benlahrech, A.; Meiser, A.; Herath, S.; Papagatsias, T.; Athanasopoulos, T.; Li, F.; Self, S.; Bachy, V.; Hervouet, C.; Logan, K.; et al. Fragmentation of SIV-gag vaccine induces broader T cell responses. PLoS One 2012, 7, e48038.
53. Stack, J.H.; Whitney, M.; Rodems, S.M.; Pollok, B.A. A ubiquitin-based tagging system for controlled modulation of protein stability. Nat. Biotechnol. 2000, 18, 1298-1302.
54. Tobery, T.W.; Siliciano, R.F. Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization. J. Exp. Med. 1997, 185, 909-920.
55. Mathiesen, I. Electropermeabilization of skeletal muscle enhances gene transfer in vivo. Gene Ther. 1999, 6, 508-514.
56. Heller, L.; Pottinger, C.; Jaroszeski, M.J.; Gilbert, R.; Heller, R. In vivo electroporation of plasmids encoding GM-CSF or interleukin-2 into existing B16 melanomas combined with electrochemotherapy induces long-term antitumour immunity. Melanoma Res. 2000, 10, 577-583.
57. Widera, G.; Austin, M.; Rabussay, D.; Goldbeck, C.; Barnett, S.W.; Chen, M.; Leung, L.; Otten, G.R.; Thudium, K.; Selby, M.J.; et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J. Immunol. 2000, 164, 4635-4640.
58. Selby, M.; Goldbeck, C.; Pertile, T.; Walsh, R.; Ulmer, J. Enhancement of DNA vaccine potency by electroporation in vivo. J. Biotechnol. 2000, 83, 147-152.
59. Otten, G.; Schaefer, M.; Doe, B.; Liu, H.; Srivastava, I.; Megede, J.Z.; O'Hagan, D.; Donnelly, J.; Widera, G.; Rabussay, D.; et al. Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine 2004, 22, 2489-2493.
60. Hirao, L.A.; Wu, L.; Khan, A.S.; Hokey, D.A.; Yan, J.; Dai, A.; Betts, M.R.; Draghia-Akli, R.; Weiner, D.B. Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine 2008, 26, 3112-3120.
61. Rosati, M.; Valentin, A.; Jalah, R.; Patel, V.; von Gegerfelt, A.; Bergamaschi, C.; Alicea, C.; Weiss, D.; Treece, J.; Pal, R.; et al. Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation. Vaccine 2008, 26, 5223-5229.
62. Sardesai, N.Y.; Weiner, D.B. Electroporation delivery of DNA vaccines: Prospects for success. Curr. Opin. Immunol. 2011, 23, 421-429.
63. Hutnick, N.A.; Myles, D.J.; Bian, C.B.; Muthumani, K.; Weiner, D.B. Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo. Curr. Opin. Virol. 2012, 1, 233-240.
64. Bodles-Brakhop, A.M.; Heller, R.; Draghia-Akli, R. Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: Current clinical developments. Mol. Ther. 2009, 17, 585-592.
65. Flingai, S.; Czerwonko, M.; Goodman, J.; Kudchodkar, S.B.; Muthumani, K.; Weiner, D.B. Synthetic DNA vaccines: Improved vaccine potency by electroporation and co-delivered genetic adjuvants. Front. Immunol. 2013, 4, doi:10.3389/fimmu.2013.00354.
66. Hallengard, D.; Brave, A.; Isaguliants, M.; Blomberg, P.; Enger, J.; Stout, R.; King, A.; Wahren, B. A combination of intradermal jet-injection and electroporation overcomes in vivo dose restriction of DNA vaccines. Genet. Vaccines Ther. 2012, 10, doi:10.1186/1479-0556-10-5.
67. Roos, A.K.; Eriksson, F.; Timmons, J.A.; Gerhardt, J.; Nyman, U.; Gudmundsdotter, L.; Brave, A.; Wahren, B.; Pisa, P. Skin electroporation: Effects on transgene expression, DNA persistence and local tissue environment. PLoS One 2009, 4, e7226.
68. Hooper, J.W.; Golden, J.W.; Ferro, A.M.; King, A.D. Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge. Vaccine 2007, 25, 1814-1823.
69. Brave, A.; Gudmundsdotter, L.; Sandstrom, E.; Haller, B.K.; Hallengard, D.; Maltais, A.K.; King, A.D.; Stout, R.R.; Blomberg, P.; Hoglund, U.; et al. Biodistribution, persistence and lack of integration of a multigene HIV vaccine delivered by needle-free intradermal injection and electroporation. Vaccine 2010, 28, 8203-8209.
70. Hutnick, N.A.; Myles, D.J.; Ferraro, B.; Lucke, C.; Lin, F.; Yan, J.; Broderick, K.E.; Khan, A.S.; Sardesai, N.Y.; Weiner, D.B. Intradermal DNA vaccination enhanced by low-current electroporation improves antigen expression and induces robust cellular and humoral immune responses. Hum. Gene Ther. 2012, 23, 943-950.
71. Lin, F.; Shen, X.; Kichaev, G.; Mendoza, J.M.; Yang, M.; Armendi, P.; Yan, J.; Kobinger, G.P.; Bello, A.; Khan, A.S.; et al. Optimization of electroporation-enhanced intradermal delivery of DNA vaccine using a minimally invasive surface device. Hum. Gene Ther. Methods 2012, 23, 157-168.
72. Kichaev, G.; Mendoza, J.M.; Amante, D.; Smith, T.R.; McCoy, J.R.; Sardesai, N.Y.; Broderick, K.E. Electroporation mediated DNA vaccination directly to a mucosal surface results in improved immune responses. Hum. Vaccin Immunother. 2013, 9, 2041-2048.
73. Heller, R.; Cruz, Y.; Heller, L.C.; Gilbert, R.A.; Jaroszeski, M.J. Electrically mediated delivery of plasmid DNA to the skin, using a multielectrode array. Hum. Gene Ther. 2010, 21, 357-362.
74. Lori, F. DermaVir: A plasmid DNA-based nanomedicine therapeutic vaccine for the treatment of HIV/AIDS. Expert Rev. Vaccines 2011, 10, 1371-1384.
75. Sullivan, S.M.; Doukas, J.; Hartikka, J.; Smith, L.; Rolland, A. Vaxfectin: A versatile adjuvant for plasmid DNA-and protein-based vaccines. Expert Opin. Drug Deliv. 2010, 7, 1433-1446.
76. Kulkarni, V.; Rosati, M.; Valentin, A.; Jalah, R.; Alicea, C.; Yu, L.; Guan, Y.; Shen, X.; Tomaras, G.D.; LaBranche, C.; et al. Vaccination with Vaxfectin® adjuvanted SIV DNA induces long-lasting humoral immune responses able to reduce SIVmac251 Viremia. Hum. Vaccin Immunother. 2013, 9, 2069-2080.
77. Templeton, N.S.; Lasic, D.D.; Frederik, P.M.; Strey, H.H.; Roberts, D.D.; Pavlakis, G.N. Improved DNA: Liposome complexes for increased systemic delivery and gene expression. Nat. Biotechnol. 1997, 15, 647-652.
78. Fuller, D.H.; Simpson, L.; Cole, K.S.; Clements, J.E.; Panicali, D.L.; Montelaro, R.C.; Murphey-Corb, M.; Haynes, J.R. Gene gun-based nucleic acid immunization alone or in combination with recombinant vaccinia vectors suppresses virus burden in rhesus macaques challenged with a heterologous SIV. Immunol. Cell Biol. 1997, 75, 389-396.
79. Aguiar, J.C.; Hedstrom, R.C.; Rogers, W.O.; Charoenvit, Y.; Sacci, J.B., Jr.; Lanar, D.E.; Majam, V.F.; Stout, R.R.; Hoffman, S.L. Enhancement of the immune response in rabbits to a malaria DNA vaccine by immunization with a needle-free jet device. Vaccine 2001, 20, 275-280.
80. Jackson, L.A.; Austin, G.; Chen, R.T.; Stout, R.; DeStefano, F.; Gorse, G.J.; Newman, F.K.; Yu, O.; Weniger, B.G. Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors. Vaccine 2001, 19, 4703-4709.
81. Williams, J.; Fox-Leyva, L.; Christensen, C.; Fisher, D.; Schlicting, E.; Snowball, M.; Negus, S.; Mayers, J.; Koller, R.; Stout, R. Hepatitis A vaccine administration: Comparison between jet-injector and needle injection. Vaccine 2000, 18, 1939-1943.
82. Boyer, J.D.; Robinson, T.M.; Kutzler, M.A.; Parkinson, R.; Calarota, S.A.; Sidhu, M.K.; Muthumani, K.; Lewis, M.; Pavlakis, G.; Felber, B.; et al. SIV DNA vaccine co-administered with IL-12 expression plasmid enhances CD8 SIV cellular immune responses in Cynomolgus macaques. J. Med. Primatol. 2005, 34, 262-270.
83. Chong, S.Y.; Egan, M.A.; Kutzler, M.A.; Megati, S.; Masood, A.; Roopchard, V.; Garcia-Hand, D.; Montefiori, D.C.; Quiroz, J.; Rosati, M.; et al. Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV(89.6P) challenge in rhesus macaques. Vaccine. 2007, 25, 4967-4982.
84. Schadeck, E.B.; Sidhu, M.; Egan, M.A.; Chong, S.Y.; Piacente, P.; Masood, A.; Garcia-Hand, D.; Cappello, S.; Roopchand, V.; Megati, S.; et al. A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques. Vaccine 2006, 24, 4677-4687.
85. Robinson, T.M.; Sidhu, M.K.; Pavlakis, G.N.; Felber, B.K.; Silvera, P.; Lewis, M.G.; Eldridge, J.; Weiner, D.B.; Boyer, J.D. Macaques co-immunized with SIVgag/pol-HIVenv and IL-12 plasmid have increased cellular responses. J. Med. Primatol. 2007, 36, 276-284.
86. Halwani, R.; Boyer, J.D.; Yassine-Diab, B.; Haddad, E.K.; Robinson, T.M.; Kumar, S.; Parkinson, R.; Wu, L.; Sidhu, M.K.; Phillipson-Weiner, R.; et al. Therapeutic vaccination with simian immunodeficiency virus (SIV)-DNA+IL-12 or IL-15 induces distinct CD8 memory subsets in SIV-infected macaques. J. Immunol. 2008, 180, 7969-7979.
87. Manrique, M.; Micewicz, E.; Kozlowski, P.A.; Wang, S.W.; Aurora, D.; Wilson, R.L.; Ghebremichael, M.; Mazzara, G.; Montefiori, D.; Carville, A.; et al. DNA-MVA vaccine protection after X4 SHIV challenge in macaques correlates with day-of-challenge antiviral CD4+ cell-mediated immunity levels and postchallenge preservation of CD4+ T cell memory. AIDS Res. Hum. Retrovir. 2008, 24, 505-519.
88. Jalah, R.; Patel, V.; Kulkarni, V.; Rosati, M.; Alicea, C.; Ganneru, B.; von Gegerfelt, A.; Huang, W.; Guan, Y.; Broderick, K.E.; et al. IL-12 DNA as molecular vaccine adjuvant increases the cytotoxic T cell responses and breadth of humoral immune responses in SIV DNA vaccinated macaques. Hum. Vaccin Immunother. 2012, 8, 1620-1629.
89. Manrique, M.; Kozlowski, P.A.; Wang, S.W.; Wilson, R.L.; Micewicz, E.; Montefiori, D.C.; Mansfield, K.G.; Carville, A.; Aldovini, A. Nasal DNA-MVA SIV vaccination provides more significant protection from progression to AIDS than a similar intramuscular vaccination. Mucosal Immunol. 2009, 2, 536-550.
90. Valentin, A.; von Gegerfelt, A.; Rosati, M.; Miteloudis, G.; Alicea, C.; Bergamaschi, C.; Jalah, R.; Patel, V.; Khan, A.S.; Draghia-Akli, R.; et al. Repeated DNA therapeutic vaccination of chronically SIV-infected macaques provides additional virological benefit. Vaccine 2010, 28, 1962-1974.
91. Calarota, S.A.; Dai, A.; Trocio, J.N.; Weiner, D.B.; Lori, F.; Lisziewicz, J. IL-15 as memory T-cell adjuvant for topical HIV-1 DermaVir vaccine. Vaccine 2008, 26, 5188-5195.
92. Manrique, M.; Kozlowski, P.A.; Cobo-Molinos, A.; Wang, S.W.; Wilson, R.L.; Mdel, P.M.-V.; Montefiori, D.C.; Carville, A.; Aldovini, A. Resistance to infection, early and persistent suppression of simian immunodeficiency virus SIVmac251 viremia, and significant reduction of tissue viral burden after mucosal vaccination in female rhesus macaques. J. Virol. 2014, 88, 212-224.
93. Manrique, M.; Kozlowski, P.A.; Cobo-Molinos, A.; Wang, S.W.; Wilson, R.L.; Montefiori, D.C.; Carville, A.; Aldovini, A. Immunogenicity of a vaccine regimen composed of simian immunodeficiency virus DNA, rMVA, and viral particles administered to female rhesus macaques via four different mucosal routes. J. Virol. 2013, 87, 4738-4750.
94. Manrique, M.; Kozlowski, P.A.; Cobo-Molinos, A.; Wang, S.W.; Wilson, R.L.; Montefiori, D.C.; Mansfield, K.G.; Carville, A.; Aldovini, A. Long-term control of simian immunodeficiency virus mac251 viremia to undetectable levels in half of infected female rhesus macaques nasally vaccinated with simian immunodeficiency virus DNA/recombinant modified vaccinia virus Ankara. J. Immunol. 2011, 186, 3581-3593.
95. Lai, L.; Kwa, S.; Kozlowski, P.A.; Montefiori, D.C.; Ferrari, G.; Johnson, W.E.; Hirsch, V.; Villinger, F.; Chennareddi, L.; Earl, P.L.; et al. Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia ankara simian immunodeficiency virus vaccine. J. Infect. Dis. 2011, 204, 164-173.
96. Lai, L.; Vodros, D.; Kozlowski, P.A.; Montefiori, D.C.; Wilson, R.L.; Akerstrom, V.L.; Chennareddi, L.; Yu, T.; Kannanganat, S.; Ofielu, L.; et al. GM-CSF DNA: An adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine. Virology 2007, 369, 153-167.
97. O'Neill, E.; Bostik, V.; Montefiori, D.C.; Kraiselburd, E.; Villinger, F. IL-12/GM-CSF coadministration in an SIV DNA prime/protein boost protocol enhances Gag-specific T cells but not virus-specific neutralizing antibodies in rhesus macaques. AIDS Res. Hum. Retrovir. 2003, 19, 883-890.
98. Hellerstein, M.; Xu, Y.; Marino, T.; Lu, S.; Yi, H.; Wright, E.R.; Robinson, H.L. Co-expression of HIV-1 virus-like particles and granulocyte-macrophage colony stimulating factor by GEO-D03 DNA vaccine. Hum. Vaccin. Immunother. 2012, 8, 1654-1658.
99. Belisle, S.E.; Yin, J.; Shedlock, D.J.; Dai, A.; Yan, J.; Hirao, L.; Kutzler, M.A.; Lewis, M.G.; Andersen, H.; Lank, S.M.; et al. Long-term programming of antigen-specific immunity from gene expression signatures in the PBMC of rhesus macaques immunized with an SIV DNA vaccine. PLoS One 2011, 6, e19681.
100. Ihata, A.; Watabe, S.; Sasaki, S.; Shirai, A.; Fukushima, J.; Hamajima, K.; Inoue, J.; Okuda, K. Immunomodulatory effect of a plasmid expressing CD40 ligand on DNA vaccination against human immunodeficiency virus type-1. Immunology 1999, 98, 436-442.
101. Liu, J.; Yu, Q.; Stone, G.W.; Yue, F.Y.; Ngai, N.; Jones, R.B.; Kornbluth, R.S.; Ostrowski, M.A. CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals. Vaccine 2008, 26, 4062-4072.
102. Franco, D.; Liu, W.; Gardiner, D.F.; Hahn, B.H.; Ho, D.D. CD40L-containing virus-like particle as a candidate HIV-1 vaccine targeting dendritic cells. J. Acquir. Immune Defic. Syndr. 2011, 56, 393-400.
103. Wang, S.W.; Bertley, F.M.; Kozlowski, P.A.; Herrmann, L.; Manson, K.; Mazzara, G.; Piatak, M.; Johnson, R.P.; Carville, A.; Mansfield, K.; et al. An SHIV DNA/MVA rectal vaccination in macaques provides systemic and mucosal virus-specific responses and protection against AIDS. AIDS Res. Hum. Retroviruses 2004, 20, 846-859.
104. Winstone, N.; Wilson, A.J.; Morrow, G.; Boggiano, C.; Chiuchiolo, M.J.; Lopez, M.; Kemelman, M.; Ginsberg, A.A.; Mullen, K.; Coleman, J.W.; et al. Enhanced control of pathogenic SIVmac239 replication in macaques immunized with a plasmid IL12 and a DNA prime, viral vector boost vaccine regimen. J. Virol. 2011, 85, 9578-9587.
105. Kalams, S.A.; Parker, S.; Jin, X.; Elizaga, M.; Metch, B.; Wang, M.; Hural, J.; Lubeck, M.; Eldridge, J.; Cardinali, M.; et al. Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults. PLoS One 2012, 7, e29231.
106. Kalams, S.A.; Parker, S.D.; Elizaga, M.; Metch, B.; Edupuganti, S.; Hural, J.; de Rosa, S.; Carter, D.K.; Rybczyk, K.; Frank, I.; et al. Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. J. Infect. Dis. 2013, 208, 818-829.
107. Tavel, J.A.; Martin, J.E.; Kelly, G.G.; Enama, M.E.; Shen, J.M.; Gomez, P.L.; Andrews, C.A.; Koup, R.A.; Bailer, R.T.; Stein, J.A.; et al. Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects. J. Acquir. Immune Defic. Syndr. 2007, 44, 601-605.
108. Wang, Z.; Troilo, P.J.; Wang, X.; Griffiths, T.G.; Pacchione, S.J.; Barnum, A.B.; Harper, L.B.; Pauley, C.J.; Niu, Z.; Denisova, L.; et al. Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation. Gene Ther. 2004, 11, 711-721.
109. Graham, B.S.; Koup, R.A.; Roederer, M.; Bailer, R.T.; Enama, M.E.; Moodie, Z.; Martin, J.E.; McCluskey, M.M.; Chakrabarti, B.K.; Lamoreaux, L.; et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J. Infect. Dis. 2006, 194, 1650-1660.
110. Mwau, M.; Cebere, I.; Sutton, J.; Chikoti, P.; Winstone, N.; Wee, E.G.; Beattie, T.; Chen, Y.H.; Dorrell, L.; McShane, H.; et al. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: Stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J. Gen. Virol. 2004, 85, 911-919.
111. Bansal, A.; Jackson, B.; West, K.; Wang, S.; Lu, S.; Kennedy, J.S.; Goepfert, P.A. Multifunctional T-cell characteristics induced by a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administration. J. Virol. 2008, 82, 6458-6469.
112. Jaoko, W.; Nakwagala, F.N.; Anzala, O.; Manyonyi, G.O.; Birungi, J.; Nanvubya, A.; Bashir, F.; Bhatt, K.; Ogutu, H.; Wakasiaka, S.; et al. Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine 2008, 26, 2788-2795.
113. Wilson, C.C.; Newman, M.J.; Livingston, B.D.; MaWhinney, S.; Forster, J.E.; Scott, J.; Schooley, R.T.; Benson, C.A. Clinical phase 1 testing of the safety and immunogenicity of an epitope-based DNA vaccine in human immunodeficiency virus type 1-infected subjects receiving highly active antiretroviral therapy. Clin. Vaccine Immunol. 2008, 15, 986-994.
114. Wang, S.; Kennedy, J.S.; West, K.; Montefiori, D.C.; Coley, S.; Lawrence, J.; Shen, S.; Green, S.; Rothman, A.L.; Ennis, F.A.; et al. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 2008, 26, 1098-1110.
115. Gorse, G.J.; Baden, L.R.; Wecker, M.; Newman, M.J.; Ferrari, G.; Weinhold, K.J.; Livingston, B.D.; Villafana, T.L.; Li, H.; Noonan, E.; et al. Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults. Vaccine 2008, 26, 215-223.
116. Eller, M.A.; Eller, L.A.; Opollo, M.S.; Ouma, B.J.; Oballah, P.O.; Galley, L.; Karnasuta, C.; Kim, S.R.; Robb, M.L.; Michael, N.L.; et al. Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy Ugandans. Vaccine 2007, 25, 7737-7742.
117. Catanzaro, A.T.; Roederer, M.; Koup, R.A.; Bailer, R.T.; Enama, M.E.; Nason, M.C.; Martin, J.E.; Rucker, S.; Andrews, C.A.; Gomez, P.L.; et al. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine 2007, 25, 4085-4092.
118. Kutzler, M.A.; Weiner, D.B. DNA vaccines: Ready for prime time? Nat. Rev. Genet. 2008, 9, 776-788.
119. Vasan, S.; Hurley, A.; Schlesinger, S.J.; Hannaman, D.; Gardiner, D.F.; Dugin, D.P.; Boente-Carrera, M.; Vittorino, R.; Caskey, M.; Andersen, J.; et al. In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS One 2011, 6, e19252.
120. Cristillo, A.D.; Weiss, D.; Hudacik, L.; Restrepo, S.; Galmin, L.; Suschak, J.; Draghia-Akli, R.; Markham, P.; Pal, R. Persistent antibody and T cell responses induced by HIV-1 DNA vaccine delivered by electroporation. Biochem. Biophys. Res. Commun. 2008, 366, 29-35.
121. Kulkarni, V.; Rosati, M.; Bear, J.; Pilkington, G.R.; Jalah, R.; Bergamaschi, C.; Singh, A.K.; Alicea, C.; Chowdhury, B.; Zhang, G.-M.; et al. Comparison of intradermal and intramuscular delivery of SIV env DNA by in vivo electroporation in macaques. Hum. Vaccin Immunother. 2013, 9, 2081-2094.
122. Kulkarni, V.; Rosati, M.; Jalah, R.; Ganneru, B.; Alicea, C.; Yu, L.; Guan, Y.; LaBranche, C.; Montefiori, D.C.; King, A.D.; et al. DNA vaccination by intradermal electroporation induces long-lasting immune responses in Rhesus macaques. J. Med. Primatol., in press.
123. Lichterfeld, M.; Yu, X.G.; le Gall, S.; Altfeld, M. Immunodominance of HIV-1-specific CD8+ T-cell responses in acute HIV-1 infection: At the crossroads of viral and host genetics. Trends Immunol. 2005, 26, 166-171.
124. Friedrich, T.C.; Valentine, L.E.; Yant, L.J.; Rakasz, E.G.; Piaskowski, S.M.; Furlott, J.R.; Weisgrau, K.L.; Burwitz, B.; May, G.E.; Leon, E.J.; et al. Subdominant CD8+ T-cell responses are involved in durable control of AIDS virus replication. J. Virol. 2007, 81, 3465-3476.
125. Liu, Y.; McNevin, J.; Rolland, M.; Zhao, H.; Deng, W.; Maenza, J.; Stevens, C.E.; Collier, A.C.; McElrath, M.J.; Mullins, J.I. Conserved HIV-1 epitopes continuously elicit subdominant cytotoxic T-lymphocyte responses. J. Infect. Dis. 2009, 200, 1825-1833.
126. Liu, J.; Ewald, B.A.; Lynch, D.M.; Nanda, A.; Sumida, S.M.; Barouch, D.H. Modulation of DNA vaccine-elicited CD8+ T-lymphocyte epitope immunodominance hierarchies. J. Virol. 2006, 80, 11991-11997.
127. Frahm, N.; Kiepiela, P.; Adams, S.; Linde, C.H.; Hewitt, H.S.; Sango, K.; Feeney, M.E.; Addo, M.M.; Lichterfeld, M.; Lahaie, M.P.; et al. Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat. Immunol. 2006, 7, 173-178.
128. Bockl, K.; Wild, J.; Bredl, S.; Kindsmuller, K.; Kostler, J.; Wagner, R. Altering an artificial gagpolnef polyprotein and mode of env co-administration affects the immunogenicity of a clade C HIV DNA vaccine. PLoS One 2012, 7, e34723.
129. Iversen, A.K.; Stewart-Jones, G.; Learn, G.H.; Christie, N.; Sylvester-Hviid, C.; Armitage, A.E.; Kaul, R.; Beattie, T.; Lee, J.K.; Li, Y.; et al. Conflicting selective forces affect T cell receptor contacts in an immunodominant human immunodeficiency virus epitope. Nat. Immunol. 2006, 7, 179-189.
130. Schneidewind, A.; Brumme, Z.L.; Brumme, C.J.; Power, K.A.; Reyor, L.L.; O'Sullivan, K.; Gladden, A.; Hempel, U.; Kuntzen, T.; Wang, Y.E.; et al. Transmission and long-term stability of compensated CD8 escape mutations. J. Virol. 2009, 83, 3993-3997.
131. Altfeld, M.; Kalife, E.T.; Qi, Y.; Streeck, H.; Lichterfeld, M.; Johnston, M.N.; Burgett, N.; Swartz, M.E.; Yang, A.; Alter, G.; et al. HLA alleles associated with delayed progression to AIDS contribute strongly to the initial CD8+ T cell response against HIV-1. PLoS Med. 2006, 3, e403.
132. Friedrich, D.; Jalbert, E.; Dinges, W.L.; Sidney, J.; Sette, A.; Huang, Y.; McElrath, M.J.; Horton, H. Vaccine-induced HIV-specific CD8+ T cells utilize preferential HLA alleles and target-specific regions of HIV-1. J. Acquir. Immune Defic. Syndr. 2011, 58, 248-252.
133. Maurer, K.; Harrer, E.G.; Goldwich, A.; Eismann, K.; Bergmann, S.; Schmitt-Haendle, M.; Spriewald, B.; Mueller, S.M.; Harrer, T. Role of cytotoxic T-lymphocyte-mediated immune selection in a dominant human leukocyte antigen-B8-restricted cytotoxic T-lymphocyte epitope in Nef. J. Acquir. Immune Defic. Syndr. 2008, 48, 133-141.
134. Li, F.; Finnefrock, A.C.; Dubey, S.A.; Korber, B.T.; Szinger, J.; Cole, S.; McElrath, M.J.; Shiver, J.W.; Casimiro, D.R.; Corey, L.; et al. Mapping HIV-1 vaccine induced T-cell responses: Bias towards less-conserved regions and potential impact on vaccine efficacy in the step study. PLoS One 2011, 6, e20479.
135. Nickle, D.C.; Rolland, M.; Jensen, M.A.; Pond, S.L.; Deng, W.; Seligman, M.; Heckerman, D.; Mullins, J.I.; Jojic, N. Coping with viral diversity in HIV vaccine design. PLoS Comput. Biol. 2007, 3, e75.
136. Nickle, D.C.; Jojic, N.; Heckerman, D.; Jojic, V.; Kirovski, D.; Rolland, M.; Pond, S.K.; Mullins, J.I. Comparison of immunogen designs that optimize peptide coverage: Reply to Fischer et al. PLoS Comput. Biol. 2008, 4, e25.
137. Barouch, D.H.; O'Brien, K.L.; Simmons, N.L.; King, S.L.; Abbink, P.; Maxfield, L.F.; Sun, Y.H.; la Porte, A.; Riggs, A.M.; Lynch, D.M.; et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat. Med. 2010, 16, 319-323.
138. Santra, S.; Liao, H.X.; Zhang, R.; Muldoon, M.; Watson, S.; Fischer, W.; Theiler, J.; Szinger, J.; Balachandran, H.; Buzby, A.; et al. Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat. Med. 2010, 16, 324-328.
139. Fischer, W.; Perkins, S.; Theiler, J.; Bhattacharya, T.; Yusim, K.; Funkhouser, R.; Kuiken, C.; Haynes, B.; Letvin, N.L.; Walker, B.D.; et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat. Med. 2007, 13, 100-106.
140. Fischer, W.; Liao, H.X.; Haynes, B.F.; Letvin, N.L.; Korber, B. Coping with viral diversity in HIV vaccine design: A response to Nickle et al. PLoS Comput. Biol. 2008, 4, e15.
141. Doria-Rose, N.A.; Learn, G.H.; Rodrigo, A.G.; Nickle, D.C.; Li, F.; Mahalanabis, M.; Hensel, M.T.; McLaughlin, S.; Edmonson, P.F.; Montefiori, D.; et al. Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope. J. Virol. 2005, 79, 11214-11224.
142. Mullins, J.I.; Nickle, D.C.; Heath, L.; Rodrigo, A.G.; Learn, G.H. Immunogen sequence: The fourth tier of AIDS vaccine design. Expert Rev. Vaccines 2004, 3, S151-S159.
143. Nickle, D.C.; Jensen, M.A.; Gottlieb, G.S.; Shriner, D.; Learn, G.H.; Rodrigo, A.G.; Mullins, J.I. Consensus and ancestral state HIV vaccines. Science 2003, 299, 1515-1518.
144. Dahirel, V.; Shekhar, K.; Pereyra, F.; Miura, T.; Artyomov, M.; Talsania, S.; Allen, T.M.; Altfeld, M.; Carrington, M.; Irvine, D.J.; et al. Coordinate linkage of HIV evolution reveals regions of immunological vulnerability. Proc. Natl. Acad. Sci. USA 2011, 108, 11530-11535.
145. Letourneau, S.; Im, E.J.; Mashishi, T.; Brereton, C.; Bridgeman, A.; Yang, H.; Dorrell, L.; Dong, T.; Korber, B.; McMichael, A.J.; et al. Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS One 2007, 2, e984.
146. Rosario, M.; Bridgeman, A.; Quakkelaar, E.D.; Quigley, M.F.; Hill, B.J.; Knudsen, M.L.; Ammendola, V.; Ljungberg, K.; Borthwick, N.; Im, E.J.; et al. Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques. Eur. J. Immunol. 2010, 40, 1973-1984.
147. De Groot, A.S.; Rivera, D.S.; McMurry, J.A.; Buus, S.; Martin, W. Identification of immunogenic HLA-B7 "Achilles' heel" epitopes within highly conserved regions of HIV. Vaccine 2008, 26, 3059-3071.
148. Wilson, C.C.; McKinney, D.; Anders, M.; MaWhinney, S.; Forster, J.; Crimi, C.; Southwood, S.; Sette, A.; Chesnut, R.; Newman, M.J.; et al. Development of a DNA vaccine designed to induce cytotoxic T lymphocyte responses to multiple conserved epitopes in HIV-1. J. Immunol. 2003, 171, 5611-5623.
149. Kaufman, D.R.; Li, F.; Cruz, A.N.; Self, S.G.; Barouch, D.H. Focus and breadth of cellular immune responses elicited by a heterologous insert prime-boost vaccine regimen in rhesus monkeys. Vaccine 2012, 30, 506-509.
150. Rosa, D.S.; Ribeiro, S.P.; Cunha-Neto, E. CD4+ T cell epitope discovery and rational vaccine design. Arch. Immunol. Ther. Exp. 2010, 58, 121-130.
151. Ribeiro, S.P.; Rosa, D.S.; Fonseca, S.G.; Mairena, E.C.; Postol, E.; Oliveira, S.C.; Guilherme, L.; Kalil, J.; Cunha-Neto, E. A vaccine encoding conserved promiscuous HIV CD4 epitopes induces broad T cell responses in mice transgenic to multiple common HLA class II molecules. PLoS One 2010, 5, e11072.
152. Almeida, R.R.; Rosa, D.S.; Ribeiro, S.P.; Santana, V.C.; Kallas, E.G.; Sidney, J.; Sette, A.; Kalil, J.; Cunha-Neto, E. Broad and cross-clade CD4+ T-cell responses elicited by a DNA vaccine encoding highly conserved and promiscuous HIV-1 M-group consensus peptides. PLoS One 2012, 7, e45267.
153. Kulkarni, V.; Valentin, A.; Rosati, M.; Alicea, C.; Singh, A.K.; Jalah, R.; Broderick, K.E.; Sardesai, N.Y.; le Gall, S.; Mothe, B.; et al. Altered immunodominance hierarchy and increased T-cell breadth upon HIV-1 conserved element DNA vaccination in macaques. PLoS One 2014, 9, e86254.
154. Hanke, T. Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines. Expert Opin. Biol. Ther. 2014, 14, 601-616.
155. Mothe, B.; Llano, A.; Ibarrondo, J.; Zamarreno, J.; Schiaulini, M.; Miranda, C.; Ruiz-Riol, M.; Berger, C.T.; Herrero, M.J.; Palou, E.; et al. CTL responses of high functional avidity and broad variant cross-reactivity are associated with HIV control. PLoS One 2012, 7, e29717.
156. Rolland, M.; Nickle, D.C.; Mullins, J.I. HIV-1 group M conserved elements vaccine. PLoS Pathog. 2007, 3, e157.
157. Kulkarni, V.; Valentin, A.; Rosati, M.; Rolland, M.; Mullins, J.I.; Pavlakis, G.N.; Felber, B.K. Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD, USA. Unpublished work, 2014.
158. Kopycinski, J.; Cheeseman, H.; Ashraf, A.; Gill, D.; Hayes, P.; Hannaman, D.; Gilmour, J.; Cox, J.H.; Vasan, S. A DNA-based candidate HIV vaccine delivered via in vivo electroporation induces CD4 responses toward the α4β7-binding V2 loop of HIV gp120 in healthy volunteers. Clin. Vaccine Immunol. 2012, 19, 1557-1559.
159. Kennedy, J.S.; Co, M.; Green, S.; Longtine, K.; Longtine, J.; O'Neill, M.A.; Adams, J.P.; Rothman, A.L.; Yu, Q.; Johnson-Leva, R.; et al. The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers. Vaccine 2008, 26, 4420-4424.
160. Goepfert, P.A.; Elizaga, M.L.; Sato, A.; Qin, L.; Cardinali, M.; Hay, C.M.; Hural, J.; DeRosa, S.C.; DeFawe, O.D.; Tomaras, G.D.; et al. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J. Infect. Dis. 2011, 203, 610-619.
161. Hayes, P.; Gilmour, J.; von Lieven, A.; Gill, D.; Clark, L.; Kopycinski, J.; Cheeseman, H.; Chung, A.; Alter, G.; Dally, L.; et al. Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults. Clin. Vaccine Immunol. 2013, 20, 397-408.
162. Gudmundsdotter, L.; Nilsson, C.; Brave, A.; Hejdeman, B.; Earl, P.; Moss, B.; Robb, M.; Cox, J.; Michael, N.; Marovich, M.; et al. Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. Vaccine 2009, 27, 4468-4474.
163. Sandstrom, E.; Nilsson, C.; Hejdeman, B.; Brave, A.; Bratt, G.; Robb, M.; Cox, J.; Vancott, T.; Marovich, M.; Stout, R.; et al. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J. Infect. Dis. 2008, 198, 1482-1490.
164. Bakari, M.; Aboud, S.; Nilsson, C.; Francis, J.; Buma, D.; Moshiro, C.; Aris, E.A.; Lyamuya, E.F.; Janabi, M.; Godoy-Ramirez, K.; et al. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. Vaccine 2011, 29, 8417-8428.
165. Borthwick, N.; Ahmed, T.; Ondondo, B.; Hayes, P.; Rose, A.; Ebrahimsa, U.; Hayton, E.J.; Black, A.; Bridgeman, A.; Rosario, M.; et al. Vaccine-elicited human T cells recognizing conserved protein regions Inhibit HIV-1. Mol. Ther. 2014, 22, 464-475.
166. Li, J.; Valentin, A.; Kulkarni, V.; Rosati, M.; Beach, R.K.; Alicea, C.; Bear, J.; Hannaman, D.; Reed, S.G.; Felber, B.K.; et al. HIV/SIV DNA vaccine combined with protein in a co-immunization protocol elicits highest humoral responses to envelope in mice and macaques. Vaccine 2013, 31, 3747-3755
167. Jaworski, J.P.; Krebs, S.J.; Trovato, M.; Kovarik, D.N.; Brower, Z.; Sutton, W.F.; Waagmeester, G.; Sartorius, R.; D'Apice, L.; Caivano, A.; et al. Co-immunization with multimeric scaffolds and DNA rapidly induces potent autologous HIV-1 neutralizing antibodies and CD8+ T cells. PLoS One 2012, 7, e31464.
168. Vargas-Inchaustegui, D.A.; Tuero, I.; Mohanram, V.; Musich, T.; Pegu, P.; Valentin, A.; Sui, Y.; Rosati, M.; Bear, J.; Kulkarni, V.; et al. Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggest novel combinatorial approaches for enhancing responses. Clin. Immunol., submitted for publication, 2014.
169. Boyer, J.D.; Robinson, T.M.; Kutzler, M.A.; Vansant, G.; Hokey, D.A.; Kumar, S.; Parkinson, R.; Wu, L.; Sidhu, M.K.; Pavlakis, G.N.; et al. Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid. Proc. Natl. Acad. Sci. USA 2007, 104, 18648-18653.
170. Muthumani, K.; Bagarazzi, M.; Conway, D.; Hwang, D.S.; Manson, K.; Ciccarelli, R.; Israel, Z.; Montefiori, D.C.; Ugen, K.; Miller, N.; et al. A Gag-Pol/Env-Rev SIV239 DNA vaccine improves CD4 counts, and reduce viral loads after pathogenic intrarectal SIV(mac)251 challenge in rhesus macaques. Vaccine 2003, 21, 629-637.
171. Boyer, J.D.; Maciag, P.C.; Parkinson, R.; Wu, L.; Lewis, M.G.; Weiner, D.B.; Paterson, Y. Rhesus macaques with high levels of vaccine induced IFN-gamma producing cells better control viral set-point following challenge with SIV239. Vaccine 2006, 24, 4498-4502.
172. Haigwood, N.L.; Pierce, C.C.; Robertson, M.N.; Watson, A.J.; Montefiori, D.C.; Rabin, M.; Lynch, J.B.; Kuller, L.; Thompson, J.; Morton, W.R.; et al. Protection from pathogenic SIV challenge using multigenic DNA vaccines. Immunol. Lett. 1999, 66, 183-188.
173. Yin, J.; Dai, A.; Lecureux, J.; Arango, T.; Kutzler, M.A.; Yan, J.; Lewis, M.G.; Khan, A.; Sardesai, N.Y.; Montefiore, D.; et al. High antibody and cellular responses induced to HIV-1 clade C envelope following DNA vaccines delivered by electroporation. Vaccine 2011, 29, 6763-6770.
174. Von Gegerfelt, A.S.; Alicea, C.; Valentin, A.; Morrow, M.; van Rompay, K.K.; Ayash-Rashkovsky, M.; Markham, P.; Else, J.G.; Marthas, M.L.; Pavlakis, G.N.; et al. Long lasting control and lack of pathogenicity of the attenuated Rev-independent SIV in rhesus macaques. AIDS Res. Hum. Retroviruses 2006, 22, 516-528.
175. Pal, R.; Wang, S.; Kalyanaraman, V.S.; Nair, B.C.; Whitney, S.; Keen, T.; Hocker, L.; Hudacik, L.; Rose, N.; Cristillo, A.; et al. Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate. J. Med. Primatol. 2005, 34, 226-236.
176. Pal, R.; Kalyanaraman, V.S.; Nair, B.C.; Whitney, S.; Keen, T.; Hocker, L.; Hudacik, L.; Rose, N.; Mboudjeka, I.; Shen, S.; et al. Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype. Virology 2006, 348, 341-353.
177. Rasmussen, R.A.; Hofmann-Lehman, R.; Montefiori, D.C.; Li, P.L.; Liska, V.; Vlasak, J.; Baba, T.W.; Schmitz, J.E.; Kuroda, M.J.; Robinson, H.L.; et al. DNA prime/protein boost vaccine strategy in neonatal macaques against simian human immunodeficiency virus. J. Med. Primatol. 2002, 31, 40-60.
178. Koopman, G.; Mortier, D.; Hofman, S.; Mathy, N.; Koutsoukos, M.; Ertl, P.; Overend, P.; van Wely, C.; Thomsen, L.L.; Wahren, B.; et al. Immune-response profiles induced by human immunodeficiency virus type 1 vaccine DNA, protein or mixed-modality immunization: Increased protection from pathogenic simian-human immunodeficiency virus viraemia with protein/DNA combination. J. Gen. Virol. 2008, 89, 540-553.
179. Hel, Z.; Nacsa, J.; Tryniszewska, E.; Tsai, W.P.; Parks, R.W.; Montefiori, D.C.; Felber, B.K.; Tartaglia, J.; Pavlakis, G.N.; Franchini, G. Containment of simian immunodeficiency virus infection in vaccinated macaques: Correlation with the magnitude of virus-specific pre-and postchallenge CD4+ and CD8+ T cell responses. J. Immunol. 2002, 169, 4778-4787.
180. Hel, Z.; Tsai, W.P.; Thornton, A.; Nacsa, J.; Giuliani, L.; Tryniszewska, E.; Poudyal, M.; Venzon, D.; Wang, X.; Altman, J.; et al. Potentiation of simian immunodeficiency virus (SIV)-specific CD4+ and CD8+ T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen. J. Immunol. 2001, 167, 7180-7191.
181. Hel, Z.; Tsai, W.P.; Tryniszewska, E.; Nacsa, J.; Markham, P.D.; Lewis, M.G.; Pavlakis, G.N.; Felber, B.K.; Tartaglia, J.; Franchini, G. Improved vaccine protection from simian AIDS by the addition of nonstructural simian immunodeficiency virus genes. J. Immunol. 2006, 176, 85-96.
182. Hutnick, N.A.; Myles, D.J.; Hirao, L.; Scott, V.L.; Ferraro, B.; Khan, A.S.; Lewis, M.G.; Miller, C.J.; Bett, A.J.; Casimiro, D.; et al. An optimized SIV DNA vaccine can serve as a boost for Ad5 and provide partial protection from a high-dose SIVmac251 challenge. Vaccine 2012, 30, 3202-3208.
183. Wilson, N.A.; Keele, B.F.; Reed, J.S.; Piaskowski, S.M.; MacNair, C.E.; Bett, A.J.; Liang, X.; Wang, F.; Thoryk, E.; Heidecker, G.J.; et al. Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge. J. Virol. 2009, 83, 6508-6521.
184. Casimiro, D.R.; Wang, F.; Schleif, W.A.; Liang, X.; Zhang, Z.Q.; Tobery, T.W.; Davies, M.E.; McDermott, A.B.; O'Connor, D.H.; Fridman, A.; et al. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag. J. Virol. 2005, 79, 15547-15555.
185. Wilson, N.A.; Reed, J.; Napoe, G.S.; Piaskowski, S.; Szymanski, A.; Furlott, J.; Gonzalez, E.J.; Yant, L.J.; Maness, N.J.; May, G.E.; et al. Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J. Virol. 2006, 80, 5875-5885.
186. Suh, Y.S.; Park, K.S.; Sauermann, U.; Franz, M.; Norley, S.; Wilfingseder, D.; Stoiber, H.; Fagrouch, Z.; Heeney, J.; Hunsmann, G.; et al. Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model. Vaccine 2006, 24, 1811-1820.
187. Liu, J.; Ewald, B.A.; Lynch, D.M.; Denholtz, M.; Abbink, P.; Lemckert, A.A.; Carville, A.; Mansfield, K.G.; Havenga, M.J.; Goudsmit, J.; et al. Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. J. Virol. 2008, 82, 4844-4852.
188. Mattapallil, J.J.; Douek, D.C.; Buckler-White, A.; Montefiori, D.; Letvin, N.L.; Nabel, G.J.; Roederer, M. Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge. J. Exp. Med. 2006, 203, 1533-1541.
189. Mattapallil, J.J.; Hill, B.; Douek, D.C.; Roederer, M. Systemic vaccination prevents the total destruction of mucosal CD4 T cells during acute SIV challenge. J. Med. Primatol. 2006, 35, 217-224.
190. Letvin, N.L.; Huang, Y.; Chakrabarti, B.K.; Xu, L.; Seaman, M.S.; Beaudry, K.; Korioth-Schmitz, B.; Yu, F.; Rohne, D.; Martin, K.L.; et al. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. J. Virol. 2004, 78, 7490-7497.
191. Seaman, M.S.; Santra, S.; Newberg, M.H.; Philippon, V.; Manson, K.; Xu, L.; Gelman, R.S.; Panicali, D.; Mascola, J.R.; Nabel, G.J.; et al. Vaccine-elicited memory cytotoxic T lymphocytes contribute to Mamu-A*01-associated control of simian/human immunodeficiency virus 89.6P replication in rhesus monkeys. J. Virol. 2005, 79, 4580-4588.
192. Sun, Y.; Schmitz, J.E.; Buzby, A.P.; Barker, B.R.; Rao, S.S.; Xu, L.; Yang, Z.Y.; Mascola, J.R.; Nabel, G.J.; Letvin, N.L. Virus-specific cellular immune correlates of survival in vaccinated monkeys after simian immunodeficiency virus challenge. J. Virol. 2006, 80, 10950-10956.
193. Yamamoto, T.; Johnson, M.J.; Price, D.A.; Wolinsky, D.I.; Almeida, J.R.; Petrovas, C.; Nason, M.; Yeh, W.W.; Shen, L.; Roederer, M.; et al. Virus inhibition activity of effector memory CD8+ T cells determines simian immunodeficiency virus load in vaccinated monkeys after vaccine breakthrough infection. J. Virol. 2012, 86, 5877-5884.
194. Letvin, N.L.; Rao, S.S.; Montefiori, D.C.; Seaman, M.S.; Sun, Y.; Lim, S.Y.; Yeh, W.W.; Asmal, M.; Gelman, R.S.; Shen, L.; et al. Immune and genetic correlates of vaccine protection against mucosal infection by SIV in monkeys. Sci. Transl. Med. 2011, 3, doi:10.1126/scitranslmed.3002351.
195. Koup, R.A.; Roederer, M.; Lamoreaux, L.; Fischer, J.; Novik, L.; Nason, M.C.; Larkin, B.D.; Enama, M.E.; Ledgerwood, J.E.; Bailer, R.T.; et al. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS One 2010, 5, e9015.
196. Kaur, A.; Sanford, H.B.; Garry, D.; Lang, S.; Klumpp, S.A.; Watanabe, D.; Bronson, R.T.; Lifson, J.D.; Rosati, M.; Pavlakis, G.N.; et al. Ability of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virus. Virology 2007, 357, 199-214.
197. Earl, P.L.; Wyatt, L.S.; Montefiori, D.C.; Bilska, M.; Woodward, R.; Markham, P.D.; Malley, J.D.; Vogel, T.U.; Allen, T.M.; Watkins, D.I.; et al. Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model. Virology 2002, 294, 270-281.
198. Amara, R.R.; Patel, K.; Niedziela, G.; Nigam, P.; Sharma, S.; Staprans, S.I.; Montefiori, D.C.; Chenareddi, L.; Herndon, J.G.; Robinson, H.L.; et al. A combination DNA and attenuated simian immunodeficiency virus vaccine strategy provides enhanced protection from simian/human immunodeficiency virus-induced disease. J. Virol. 2005, 79, 15356-15367.
199. Robinson, H.L.; Montefiori, D.C.; Villinger, F.; Robinson, J.E.; Sharma, S.; Wyatt, L.S.; Earl, P.L.; McClure, H.M.; Moss, B.; Amara, R.R. Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine. Virology 2006, 352, 285-294.
200. Zhao, J.; Lai, L.; Amara, R.R.; Montefiori, D.C.; Villinger, F.; Chennareddi, L.; Wyatt, L.S.; Moss, B.; Robinson, H.L. Preclinical studies of human immunodeficiency virus/AIDS vaccines: Inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia. J. Virol. 2009, 83, 4102-4111.
201. Barouch, D.H.; Liu, J.; Li, H.; Maxfield, L.F.; Abbink, P.; Lynch, D.M.; Iampietro, M.J.; SanMiguel, A.; Seaman, M.S.; Ferrari, G.; et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012, 482, 89-93.
202. Vaccari, M.; Boasso, A.; Ma, Z.M.; Cecchinato, V.; Venzon, D.; Doster, M.N.; Tsai, W.P.; Shearer, G.M.; Fuchs, D.; Felber, B.K.; et al. CD4+ T-cell loss and delayed expression of modulators of immune responses at mucosal sites of vaccinated macaques following SIV(mac251) infection. Mucosal Immunol. 2008, 1, 497-507.
203. Vaccari, M.; Mattapallil, J.; Song, K.; Tsai, W.P.; Hryniewicz, A.; Venzon, D.; Zanetti, M.; Reimann, K.A.; Roederer, M.; Franchini, G. Reduced protection from simian immunodeficiency virus SIVmac251 infection afforded by memory CD8+ T cells induced by vaccination during CD4+ T-cell deficiency. J. Virol. 2008, 82, 9629-9638.
204. Cox, J.H.; Ferrari, M.G.; Earl, P.; Lane, J.R.; Jagodzinski, L.L.; Polonis, V.R.; Kuta, E.G.; Boyer, J.D.; Ratto-Kim, S.; Eller, L.A.; et al. Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge. Vaccine 2012, 30, 1830-1840.
205. Virnik, K.; Hockenbury, M.; Ni, Y.; Beren, J.; Pavlakis, G.N.; Felber, B.K.; Berkower, I. Live attenuated rubella vectors expressing SIV and HIV vaccine antigens replicate and elicit durable immune responses in rhesus macaques. Retrovirology. 2013, 10, doi:10.1186/1742-4690-10-99.
206. Von Gegerfelt, A.S.; Rosati, M.; Alicea, C.; Valentin, A.; Roth, P.; Bear, J.; Franchini, G.; Albert, P.S.; Bischofberger, N.; Boyer, J.D.; et al. Long-lasting decrease in viremia in macaques chronically infected with simian immunodeficiency virus SIVmac251 after therapeutic DNA immunization. J. Virol. 2007, 81, 1972-1979.
207. Palma, P.; Romiti, M.L.; Montesano, C.; Santilli, V.; Mora, N.; Aquilani, A.; Dispinseri, S.; Tchidjou, H.K.; Montano, M.; Eriksson, L.E.; et al. Therapeutic DNA vaccination of vertically HIV-infected children: Report of the first pediatric randomised trial (PEDVAC). PLoS One 2013, 8, e79957.
208. Rodriguez, B.; Asmuth, D.M.; Matining, R.M.; Spritzler, J.; Jacobson, J.M.; Mailliard, R.B.; Li, X.D.; Martinez, A.I.; Tenorio, A.R.; Lori, F.; et al. Safety, tolerability, and immunogenicity of repeated doses of dermavir, a candidate therapeutic HIV vaccine, in HIV-infected patients receiving combination antiretroviral therapy: Results of the ACTG 5176 trial. J. Acquir. Immune Defic. Syndr. 2013, 64, 351-359.
209. Casazza, J.P.; Bowman, K.A.; Adzaku, S.; Smith, E.C.; Enama, M.E.; Bailer, R.T.; Price, D.A.; Gostick, E.; Gordon, I.J.; Ambrozak, D.R.; et al. Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire. J. Infect. Dis. 2013, 207, 1829-1840.
210. Lisziewicz, J.; Bakare, N.; Calarota, S.A.; Banhegyi, D.; Szlavik, J.; Ujhelyi, E.; Toke, E.R.; Molnar, L.; Lisziewicz, Z.; Autran, B.; et al. Single DermaVir immunization: Dose-dependent expansion of precursor/memory T cells against all HIV antigens in HIV-1 infected individuals. PLoS One 2012, 7, e35416.
211. Carcelain, G.; Autran, B. Immune interventions in HIV infection. Immunol. Rev. 2013, 254, 355-371.
212. Gudmundsdotter, L.; Sjodin, A.; Bostrom, A.C.; Hejdeman, B.; Theve-Palm, R.; Alaeus, A.; Lidman, K.; Wahren, B. Therapeutic immunization for HIV. Springer Semin. Immunopathol. 2006, 28, 221-230.